Alliqua BioMedical, Inc. Form 4 September 16, 2014

OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Washington, D.C. 20549 Number: Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

(Print or Type Responses)

if no longer

Section 16.

Form 4 or

Form 5

1(b).

subject to

1. Name and A POSNER B	Person <u>*</u> 2. Issue Symbol	2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer		
		1		cal, Inc. [ALQA]	(Che	eck all applicable	e)
(Last)	(First) (M	Aiddle) 3. Date c	f Earliest Tı	ansaction			
			Day/Year)		Director		b Owner
C/O ALLIQ	AL, 09/15/2	09/15/2014			ve title Oth	er (specify	
INC., 2150	WEST,				below) below) Chief Financial Officer		
SUITE B					Chiler		
	4. If Am	4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check		
		Filed(Mo	nth/Day/Year)	Applicable Line) _X_ Form filed by		
LANGHOR	RNE, PA 19047				Form filed by Person	More than One Re	eporting
(City)	(State)	(Zip) Tab	le I - Non-E	Derivative Securities Acc	quired, Disposed o	of, or Beneficial	lly Owned
1.Title of	2. Transaction Date	e 2A. Deemed	3.	4. Securities Acquired	5. Amount of	6. Ownership	7. Nature of
Security	(Month/Day/Year)	Execution Date, if	Transacti	on(A) or Disposed of	Securities	Form: Direct	Indirect
(Instr. 3)		any	Code	(D)	Beneficially	(D) or	Beneficial
		(Month/Day/Year)	(Instr. 8)	(Instr. 3, 4 and 5)	Owned	Indirect (I)	Ownership
					Following	(Instr. 4)	(Instr. 4)
				(A)	Reported		
				or	Transaction(s)		
			Code V	Amount (D) Price	(Instr. 3 and 4)		

Common \$ 09/15/2014 Ρ 2,000 7,640 А Stock 4.94

Code V

Amount (D)

Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3235-0287

January 31,

2005

0.5

Expires:

response...

Estimated average

burden hours per

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans	
					(Instr. 3, 4, and 5)						(Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		
Repo	rting O	wners									

Reporting Owner Name / Address		Relationships					
For8 o	Director	10% Owner	Officer	Other			
POSNER BRIAN M C/O ALLIQUA BIOMEDICAL, INC. 2150 CABOT BLVD. WEST, SUITE B LANGHORNE, PA 19047				Chief Financial Officer			
Signatures							
/s/ Brian Posner	09/16/2014						
**Signature of	Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: Alliqua BioMedical, Inc. - Form 4

Reporting Person